Bombay HC Slams Maharashtra FDA Over Cipla Licence Cancellation, Regulator Withdraws Order Against Pune Facility
The Maharashtra Food and Drug Administration (FDA) on Saturday withdrew its order cancelling the drug sale licence of Cipla Pharma & Life Sciences Ltd’s carrying and forwarding (C&F) facility in Pune, after the Bombay High Court criticised the regulator for acting in a “high-handed” manner and “going overboard”. Court Says FDA Failed To Follow Due Process A bench of Acting Chief Justice Ravindra…
On Saturday, the Bombay High Court intervened in a dispute between the Maharashtra Food and Drug Administration (FDA) and Cipla Pharma & Life Sciences Ltd. The court criticized the FDA for its "high-handed" actions and withdrawal of a drug sale licence for the company's C&F facility in Pune. The FDA had cancelled the licence citing several irregularities, including packaging, storage, records, and recall issues with Reactin Plus Tablets.
Cipla challenged the decision, stating that the regulator had contacted the company on a public holiday without providing an opportunity for a hearing. The court questioned the FDA's decision to call the company on a holiday and then proceed to pass the cancellation order on the same day. The bench of Acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad observed that the FDA had failed to follow due process and acted contrary to the principles of natural justice.
The FDA has now withdrawn its cancellation order and will issue a fresh show-cause notice to Cipla, followed by a reasoned order after considering the company's response.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
